Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
#3040 Palliative CT Brachytherapy in Hepatic Metastatic NET
Introduction: Hepatic metastases of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) may induce prognosis relevant complications in an otherwise stable systemic disease after resection of the primary.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Jann H
Authors: Feldhaus F, Jann H, Jonczyk M, Boening G, Wieners G,
Keywords: brachytherapy, afterloading, hepatic metastases, local tumor ablation, local tumor control,
Introduction: Debulking surgery, TAE and TACE procedures are undertaken in patients with metastatic NETs. Reducing the physical burden of disease may prolong survival and can improve the quality of life of patients. However, there is only limited quality of life data available after surgery despite the fact that is has been used routinely for many years.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Sinclair A, Tanno L, Jarvis E, Ramsey E, Naheed S,
Keywords: Quality of Life, Debulking Surgery, TAE, TACE, Metastatic, NETs,
Introduction: In the NETTER-1 study, peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE increased progression-free survival (PFS) and time to deterioration in quality of life (QoL) in patients with advanced midgut neuroendocrine tumours (NETs), compared with octreotide.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Keywords: 177Lu-DOTATATE, metastases, quality of life,
Introduction: RECIST 1.1 criteria have been challenged for the evaluation of treatment response in NET.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: de Mestier L, Dromain C, Lamarca A, La Salvia A, Op de Beeck B,
Keywords: imaging criteria, response evaluation, CT scan,
Introduction: Peptide receptor radionuclide therapy (PRRT) usually leads to stable rather than decreased lesion size in neuroendocrine tumors (NETs), therefore RECIST criteria are not used to assess early response to treatment.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Song H, Kunz P, Fisher G, Franc B, Moradi F,
Keywords: PRRT, 68Ga-DOTATATE PET/CT, Neuroendocrine tumor,